Sandbox Reserved 1487
From Proteopedia
(Difference between revisions)
Line 47: | Line 47: | ||
The aim was to develop a gene encoding an enzyme that performs an activity normally absent in the target cells of the therapy. This enzyme would then allow the synthesis of toxic compounds. | The aim was to develop a gene encoding an enzyme that performs an activity normally absent in the target cells of the therapy. This enzyme would then allow the synthesis of toxic compounds. | ||
- | Aciclovir (ACV) and Ganciclovir (GVC) are 2 nucleosides analogues of guanosine. These are metabolized by HSV1-TK to a monophosphoryl compound which is then transformed into di and tri phosphate metabolites by cellular kinases. Then, ACV-TP and GVC-TP are incorporated into DNA during the elongation causing the death of infected cells by apoptosis. They also inhibit the viral replication. Death of cells is also triggered when they are treated with GVC when there has been an upstream transfection of the HSV1-TK gene outside a viral infection. | + | Aciclovir (ACV) and Ganciclovir (GVC) are 2 nucleosides analogues of guanosine. These are metabolized by HSV1-TK to a monophosphoryl compound which is then transformed into di and tri phosphate metabolites by cellular kinases. Then, ACV-TP and GVC-TP are incorporated into DNA during the elongation causing the death of infected cells by apoptosis. They also inhibit the viral replication. Death of cells is also triggered when they are treated with GVC when there has been an upstream transfection of the HSV1-TK gene outside a viral infection. <ref>http://www.ipubli.inserm.fr/bitstream/handle/10608/1401/1999_5_625.pdf?sequence=4</ref> |
Revision as of 18:26, 10 January 2019
This Sandbox is Reserved from 06/12/2018, through 30/06/2019 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1480 through Sandbox Reserved 1543. |
To get started:
More help: Help:Editing |
Your Heading Here (maybe something like 'Structure')
|
References
- ↑ https://tel.archives-ouvertes.fr/tel-00720223/document
- ↑ https://www.uniprot.org/uniprot/P03176
- ↑ https://www.rcsb.org/structure/1KI4
- ↑ https://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=1KI4¶ms.chainEntityStrategyStr=all&forcePageForChain=A¶ms.annotationsStr=SCOP,Site%20Record,DSSP¶ms.chainsPerPage=2
- ↑ https://www.ebi.ac.uk/pdbe/entry/pdb/1ki4/analysis
- ↑ https://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=1KI4¶ms.chainEntityStrategyStr=all&forcePageForChain=A¶ms.annotationsStr=SCOP,Site%20Record,DSSP¶ms.chainsPerPage=2
- ↑ https://www.rcsb.org/structure/1KI4
- ↑ https://www.ebi.ac.uk/pdbe/entry/pdb/1ki4/bound/SO4#3A
- ↑ https://www.ebi.ac.uk/pdbe/entry/pdb/1ki4/bound/BTD
- ↑ https://www.rcsb.org/structure/1KI4
- ↑ Champness JN, Bennett MS, Wien F, Visse R, Summers WC, Herdewijn P, de Clerq E, Ostrowski T, Jarvest RL, Sanderson MR. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins. 1998 Aug 15;32(3):350-61. PMID:9715911
- ↑ http://www.ipubli.inserm.fr/bitstream/handle/10608/1401/1999_5_625.pdf?sequence=4